ArticleBMC cancer2026
CCDC6, a ferroptosis-related gene, modulates stemness features of pancreatic cancer cells in vitro.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivePancreatic cancer (PC) poses a significant threat to patient quality of life. Ferroptosis, a novel form of non-apoptotic cell death, is implicated in pancreatic tumorigenesis and therapy resistance. This study aims to identify key ferroptosis-related genes (FRGs) as prognostic biomarkers, to construct a risk model for predicting patient outcomes, and to explore the underlying biological mechanisms.
methodsWe integrated transcriptomic and single-cell RNA sequencing (scRNA-seq) data to develop a prognostic model. We used cross-validation across three machine learning algorithms to identify core FRGs with high prognostic value. A risk prediction model was then constructed and validated using independent datasets. Immunological profiling was conducted to characterize the tumor microenvironment of different risk groups. In vitro experiments, including gene knockdown and spheroid formation assays, were performed to functionally validate the role of a key gene.
resultsCross-validated analysis identified YAP1, CCDC6, and CIRBP as pivotal prognostic FRGs. The risk prediction model based on these genes demonstrated clinically satisfactory performance, particularly for long-term survival, and was robustly validated. Immunological profiling revealed that high-risk patients exhibited elevated expression of immune checkpoint molecules CEACAM1 and LGALS3, whereas the low-risk group was enriched for myogenesis features. Experimentally, we confirmed CCDC6 overexpression in pancreatic cancer cells. CCDC6 knockdown suppressed the stemness markers NANOG and SOX2 and reduced cancer cell self‑renewal. It also downregulated GPX4 and SLC7A11. Treatment with the ferroptosis inhibitor Ferrostatin-1 partially restored the stemness markers, suggesting that CCDC6 sustains stemness-associated traits at least in part through ferroptosis regulation.
conclusionThis study establishes a robust FRGs-based prognostic model for pancreatic cancer. In vitro, CCDC6 knockdown downregulated GPX4 and SLC7A11, and ferroptosis inhibition partially rescued stemness marker loss, suggesting that CCDC6 may link ferroptosis defense to stemness maintenance. These findings warrant further in vivo validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.